CATX -
Perspective Therapeutics, Inc.
Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
4.86 0.14 (2.88%) |
--- |
-0.01 (-0.2%) |
0.0 (0.0%) |
0.09 (1.85%) |
0.1 (2.04%) |
-0.06 (-1.19%) |
-0.06 (-1.19%) |
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Earnings & Ratios
- Basic EPS:
- -0.25
- Diluted EPS:
- -0.25
- Basic P/E:
- -20.0
- Diluted P/E:
- -20.0
- RSI(14) 1m:
- 48.85
- VWAP:
- 5.01
- RVol:
- 0.8788
Events
Period |
Kind |
Movement |
Occurred At |
1m |
Price increase 1m |
5.05 +0.1 (+1.95%) |
Oct 15 09:31 |
1m |
Price increase 1m |
4.98 +0.08 (+1.63%) |
Oct 15 09:30 |
Related News
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
Jul 23, 2025 13:26
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
Jul 15, 2025 11:00
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
Jun 21, 2025 12:00
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
Apr 17, 2025 11:00
Pharma-Biotech Market Development Analysis Report 2025: Growth Opportunities Shaped by a Convergence of Scientific Innovation, Regulatory Evolution, and Market Pressures
Apr 01, 2025 12:00
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Mar 17, 2025 11:00
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
Feb 21, 2025 12:00
Perspective Therapeutics to Participate in Upcoming February Investor Conferences
Feb 05, 2025 12:00
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium
Jan 24, 2025 12:00
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials
Dec 16, 2024 15:53